abstract: From early embryonic life, anti-Müllerian hormone (AMH) is produced by Sertoli cells and is essential for male sex differentiation.
Introduction
Anti-Müllerian hormone (AMH) belongs to the transforming growth factor beta (TGF-b) family of growth factors that show a pronounced temporal difference in expression between males and females. In males, AMH is produced by the Sertoli cells from the onset of testicular differentiation in early fetal life and secures regression of the Müllerian duct derivatives (Josso et al., 1993; Al-Attar et al., 1997) . AMH can be detected in the Sertoli cell cytoplasm from week 6 post conception (pc) and the concentrations of AMH in the circulation of male fetuses during mid-gestation have been reported to be around 60-90 ng/ml, whereas it is absent in female fetuses (Lutterodt et al., 2009) . In males, the concentration of AMH rises the first month after birth, reaching a peak level at 6 months of age, after which it declines during childhood and reaches a basal level at puberty (Matuszczak et al., 2013) .
In females, AMH is produced by immature granulosa cells (GCs) in developing follicles from late gestation to the end of the reproductive life (Dewailly et al., 2014) . A definitive function of AMH in females has not yet been established. In female mice, AMH has been suggested to function as an inhibitor of primordial follicle recruitment and attenuate the sensitivity of pre-antral follicles to the FSH-dependent selection for growth (Durlinger et al., 2001 (Durlinger et al., , 2002 . In mono-ovulating species, like the sheep, AMH has been suggested to undertake several functions, which include a reduction in the rate of FSH-dependent follicle growth (Campbell et al., 2012) , but AMH may also function as an aromatase inhibitor, decreasing the conversion of androgens into estrogens (Vigier et al., 1989; Nielsen et al., 2011) . By reducing the estradiol output, AMH thus may act as a gatekeeper to ensure that each small antral follicle produces little estradiol prior to selection (i.e. up to a follicular diameter of 8 mm in humans). The relative quiescence of the small follicle estradiol output allows a direct ovarian/pituitary dialogue regulating the development of the selected follicle, which later on will ovulate (Jeppesen et al., 2013) .
AMH is secreted as a 140-kDa homodimeric precursor, consisting of two identical 70-kDa monomers. Each monomer consists of two parts: (i) a 25-kDa mature C-terminal region, which becomes bioactive after proteolytic cleavage and binds the AMH receptor II (AMHRII), inducing intracellular Smad-signalling (di Clemente et al., 2010) , and (ii) a proregion, which is important in AMH synthesis and the extracellular transport. The AMH precursor is cleaved at amino acid (aa) 451 between the two domains. An additional cleavage site at aa 229 in the pro-region is known, giving rise to three potential cleavage products: pro-mid-mature, mid-mature and mature (Pepinsky et al., 1988; Donahoe, 1992;  Fig. 1 ). After cleavage, the mature C-terminal is biologically active when noncovalently associated with the pro-region (this form is termed 'promature AMH' in this study). Further proteolytic cleavage of pro-mature AMH results in dissociation of the pro-region from the mature C-terminal (Fig. 1) . Unlike other members of the TGF-b family, the proregion of the cleaved AMH enhances the activity of the mature C-terminal when the two cleaved peptides remain associated (i.e. promature AMH; Pepinsky et al., 1988; di Clemente et al., 2010; Pankhurst and McLennan, 2013) .
Previously, the lack of specific well-characterized antibodies specific for the different forms of human AMH has held back a detailed understanding concerning the physiological distribution of the active-and non-active forms in humans. Therefore, to assess the distribution of the different AMH forms, we have tested five novel high-affinity monoclonal antibodies, specific for either the mature C-terminal form or the pro-region of AMH. Human fetal testis and immature GCs from small antral follicles were analysed by immunofluorescence microscopy (IFM), immunohistochemistry (IHC) and western blotting (WB).
Materials and Methods

Monoclonal antibodies towards AMH
Mouse monoclonal antibodies 39/1, 39/29, 39/39, 39/48 and 39/72 (hereafter named: AMH-1, AMH-29, AMH-39, AMH-48 and AMH-72, respectively) were developed by immunizing female AMH-deficient mice with recombinant human AMH (BA-047, Ansh Labs, Webster, TX, USA), preparations as described previously (Robertson et al., 2014) . The monoclonal antibodies were screened on mature C-terminal AMH (BA-048, Ansh Labs, Webster, TX, USA), pro-AMH (BA-049, Ansh Labs), human pro-mature AMH complex (BA-047, Ansh Labs) and rat AMH (BA-053, Ansh Labs) as previously described by Robertson et al. (2014) .
Epitope mapping
The specificity of the AMH antibodies was investigated by assessing their binding to 80 overlapping biotinylated peptides across the precursor AMH molecule (http://www.uniprot.org/uniprot/P03971) as described previously (Robertson et al., 2014) . The peptides were synthesized by Mimotopes Pty Ltd (Clayton, Victoria, Australia), each 12 aa long with an overlap of 4 aa. An additional 4 aa spacer consisting of a serineglycine repeat with an N-terminal biotin was attached to the N-terminus of each peptide (Table I) . The assay to assess the ability of the biotinylated peptides to bind the monoclonal antibodies was as follows: 80 peptides covering the entire sequence of AMH were individually dissolved in dimethylsulphoxide, diluted in phosphate-buffered saline (PBS) with Tween-20 and sodium azide. Individual peptide samples were incubated on avidin-coated plates, added antibody, followed by horse-radish peroxidase (HRP)-goatanti-mouse IgG, visualized with 3,3 ′ ,5,5 ′ -tetramethylbenzidine. Absorbance at 450 nm was measured and plotted against the individual peptide sequence. The epitope binding sites are illustrated on the full length AMH sequence of both the human and mouse protein (Supplementary data, Figs S1 and S2).
Figure 1
Diagram show the processing of AMH and the binding sites of the tested AMH antibodies. AMH is produced as a homodimeric non-active precursor, which has to be cleaved to become active. Binding of the pro-mature non-covalent complex to the receptor causes the pro-region to dissociate. Yellow IgG molecules indicate the binding sites of the tested antibodies.
Selection of monoclonal antibodies
The antibodies were selected based on the selective binding of the linear epitopes to different parts of the AMH molecule. AMH-1 and AMH-29 binds specific to epitopes on the mature C-terminal of AMH, which becomes unmasked after proteolytic cleavage and dissociation of the pro-and mature regions, though AMH-1 have a weak recognition at the pro-region. AMH-39/48/72 binds specific to epitopes on the pro-region (Table I ). For comparison, the commercially available AMH antibody C-20 (Santa Cruz Biotechnology, CA, USA) detecting AMH at 70 kDa was also used.
Sample collection and preparation
Human fetal testes
Testes from human embryos and fetuses, aged 8 -19 weeks pc, were obtained from either the archives of the Department of Cellular and Molecular Medicine (ICMM) at the University of Copenhagen or from tissue obtained from legal abortions performed at the Department of Obstetrics and Gynaecology, Skejby Sygehus, Denmark, in collaboration with the Laboratory of Reproductive Biology, Rigshospitalet, Denmark. Only healthy women above the age of 18 years, who have decided to terminate pregnancy for other reasons than fetal abnormality, were asked to participate. All included embryos and fetuses appeared morphologically normal.
Immediately after the surgical procedure, the fetus were either fixed in Bouin's fixative for 24 h or the gonads were isolated and fixed for 12 -24 h in either 10% neutral buffered formalin, 4% Formol-Calcium, Lillie's or Bouin's fixatives, processed for paraffin embedding and cut into serial sections (5 mm). Crown-rump lengths of the embryos and fetuses were measured in connection with the surgical procedure and ages were determined in days or weeks pc. Fetal sex were determined by morphology of the gonads and verified by polymerase chain reaction technique (Nakahori et al., 1991) . Male sex was verified by the presence of the SRY gene (primers: Fwd: 5 ′ -GCT TTG AGT GGC TGT A-3 ′ , Rev: 5 ′ -TTG CAG TTT GCT TCC CGC A-3 ′ ). As control gene, beta-actin was used (primers: Fwd: 5 ′ -ACA AGA GAG CAG GTT TGG AG-3 ′ , Rev: 5 ′ -CTG TAT GAC CTT TCT GTG CC-3 ′ ).
Human fetal serum from second trimester pregnancies
Fetal blood samples were obtained in order to confirm the results of prenatal genetic diagnosis from amniotic fluid cells or in connection with an intrauterine transfusion. Ultrasound-guided umbilical cord blood samples (i.e. cordocentesis) from three female and four male fetuses aged 15 -28 weeks pc were collected. The cordocentesis samples comprised a total volume of few hundred microliters, which after the isolation of the serum was stored at 2808C for further analysis. Data on these samples have previously been published (Lutterodt et al., 2009 ).
Mouse post-natal
Mouse testes aged 3 days post-partum was obtained, dissected free, washed in PBS, snap frozen in liquid nitrogen and stored at 2808C for WB analysis.
Human GCs
GCs were isolated by the aspiration of individual follicles from ovaries surgically removed for fertility preservation (Rosendahl et al., 2011; Andersen et al., 2012) . Fertility preservation of the ovarian cortex was offered to women diagnosed with a disease in which the appropriate treatment was going to be gonadotoxic and rendered the woman at risk of losing her fertility.
GCs from a total number of 27 follicles were collected. The GC's were either washed twice in PBS and stored at 2808C for further WB analysis or cultured for IFM analysis. Pieces of ovarian medulla tissue, which are not suitable for preservation, containing pre-antral and early antral follicles were collected and fixated in Bouin's fixative before embedded in paraffin and cut into serial sections (5 mm) for IHC.
Culture of GCs
Human GCs from eight follicles were seeded into wells mounted on eight well chamber slides (C-7057, Sigma Aldrich, Brøndby, Denmark) and cultured in minimal essential medium alpha with 10% calf serum, enriched with 1% Penicillin -Streptomycin (15070-063, Gibco, Paisley, Scotland), 1% Insulin-SelenTransferrin (41400-045, Gibco), 1% Glutamax (35050-038, Gibco), at 378C in a 10% CO 2 -incubator for 20 h. After the culture period, the GCs were fixated in formalin for 10 min at room temperature (RT), washed twice in Tris-buffered saline (TBS) and processed for IFM.
Immunohistochemical detection of AMH forms in male fetal tissue and adult ovaries
Paraffin-embedded human fetal testes, a transverse section of a male fetus including the testis region and pre-antral follicles were de-paraffinated in xylene, dehydrated and prepared as 5 mm serial sections for IHC. Antigens were retrieved in citrate buffer before incubation with primary antibodies (AMH-39, AMH-48, AMH-72 1:100-1:1000; AMH-29 and AMH-1 1:50-1:500) for 1 h at RT and antibodies were diluted in TBS supplemented with 5% bovine serum albumin (BSA; Sigma Aldrich). Sections were washed in ddH 2 O and further incubated with rabbit-anti-mouse-HRP secondary antibody (Dako, Glostrup, Denmark, 1:200) for 30 min at RT and visualized by peroxidise reaction with 3,3 ′ -diaminobenzidine tetrahydrochloride (Dako). Images were captured on an Olympus IX70 inverted microscope with a Canon EOS 1100D single lens reflex; 12,2 megapixel; 4272 × 2848 resolution camera with EOS Utility software.
Immunofluorescence
Fetal testicular sections were de-paraffinated in xylene and dehydrated before processing for IFM analysis. GCs and fetal testicular tissue were permeabilized in 0.25% Triton X-100 in TBS, quenched in TBS, blocked in TBS with 1% BSA (Sigma Aldrich) and incubated in primary antibody solutions (AMH-29/39/48/72) for 1 h at RT according to Blum et al. (2012) . Primary antibodies including AMH-29 (1:50), AMH-39 (1:200), AMH-48, AMH-72 (1:100) and AMH C-20 (1:200, Santa Cruz Biotechnology) diluted in TBS with 1% BSA were used. Cells and tissue were washed three times in TBS before incubation with goat-anti-mouse IgG Alexa 488 or donkey-anti-goat IgG Alexa 488 (both 1:1000, Molecular Probes, Invitrogen, Taastrup, Denmark) for 1 h. Cells and tissue were washed twice, nuclear counterstained with TO-PRO w -3 (1:500, Molecular Probes, Life Technologies, Naerum, Denmark), washed once and mounted in ProLong 
Anti-Mü llerian hormone ELISA
A newly developed 24/32 pico AMH ELISA (Ansh Labs, AL-124) with enhanced sensitivity, directed to epitope regions located in the mid-and mature AMH regions, was used. The 24/32 pico ELISA detected precursor AMH and pro-mature AMH as described previously (Robertson et al., 2014) .
SDS -polyacrylamide gel electrophoresis and western blot analysis
GCs from 19 small antral follicles were collected in connection with ovary cryopreservation for fertility preservation. The GCs were pooled and washed twice in 1 ml PBS followed by centrifugation at 300g for 5 min, and the supernatant were removed before storage at 2808C for further analysis. Mature cumulus cells from seven participants collected in connection with IVF treatment were pooled, washed twice in PBS, centrifuged at 300g for 5 min and the supernatant was removed before storage at 2808C for further analysis. One human fetal testis aged 9 weeks pc and a three mouse testes aged 3 days post-partum were dissected and washed three times in PBS, snap frozen in liquid nitrogen and stored at 2808C for further analysis. All samples were lysed in Radio-Immmuno Precipitation Assay (RIPA) buffer and the testes were further homogenized by a tissue lyser with 5 mm stainless steel beads (TissueLyser, Qiagen, Copenhagen, Denmark) or by sonication. As a control, human plasmin-cleaved AMH was used (Biogen, Hillerød, Denmark). Protein concentrations were measured using a DC-protein assay (BioRAD Laboratories, Copenhagen, Denmark) using human serum albumin as a standard (CSL Behring, Marburg, Germany). Proteins were separated by gel electrophoresis using a XCell SureLock TM system (Invitrogen) under denaturing and reducing conditions on 4 -12% NuPAGE Bis -Tris gels (NP0323BOX, Invitrogen) with 2-(N-morpholino)ethanesulfonic acid SDS-running buffer and transferred to polyvinylidene difluoride (PVDF) membranes (LC2005, Invitrogen). Western blot analyses were performed according to Friedrichsen et al. (2010) with slight modifications. In brief, PVDF membranes were washed in TBS with 0.1% Tween-20, incubated in primary antibody (1:1000 AMH-39/48/72; 1:500 AMH-29; 1:500 b-actin, Abcam, Cambridge, UK) for 60 min, washed in TBST, blocked in Western Blocker Solution (Sigma Aldrich) for 20 min, incubated in secondary antibody goat-anti-mouse-AP (1:2500, Sigma Aldrich) and goat-anti-Rabbit-AP (1:2000, Jackson ImmunoResearh, Skanderborg, Denmark) for 30 min and visualized using the Pierce-Nitro blue tetrazolium/5-Bromo-4-chloro-3-indolyl phosphate solution (Thermo Fisher Scientific, Hvidovre, Denmark). For blocking, the recombinant pro-mature-associated AMH form (Ansh Labs, BA047) was incubated with the primary antibody over night at 48C.
Ethical approval
All participating women received oral and written information according to and approved by 'The Scientific Ethical Committee for the Capital Region' [KF (01) 
Results
By IHC, IFM and WB, the antibodies AMH-29 and AMH-1 showed strong affinity to the mature C-terminal AMH, whereas no binding to the precursor AMH and pro-mature AMH was observed. In contrast, the antibodies AMH-39, AMH-48 and AMH-72 showed strong affinity to the pro-mature AMH form, but no binding to the precursor AMH or mature C-terminal AMH (Fig. 1) .
Immunohistochemical staining of AMH forms in human fetal testis All three antibodies binding the pro-mature AMH form (AMH-39/48/72, 1:200) stained the cytoplasm of Sertoli cells from human fetal testes (Fig. 2) . Staining with antibody concentrations up to 1:1000 were made on neighbouring serial sections with similar results, data not shown. In contrast, at all developmental stages (week 8-19 pc), the mature C-terminal form of AMH (i.e. antibody AMH-29 and AMH-1) was not detected in Sertoli cells (AMH-1 not shown; Fig. 2) , though a faint staining was detectable at the highest primary antibody concentration (1:50) in one specimen (Fig. 3) .
A transverse section of one entire human male fetus aged 8 weeks pc showed a faint staining of mature C-terminal AMH exclusively in the testis and mesonephros (Fig. 3) . Pro-mature AMH (detected with AMH-39/ 48/72) was strongly expressed in the testis, illustrated by AMH-48 (Fig. 3) . A transverse section of the same fetus including the mesonephritic area expressed pro-mature AMH strongly in the Sertoli cell cytoplasm. Pro-mature AMH expression in the tubuli of mesonephros was also found. A faint expression of C-terminal AMH (detected by AMH-29) was found in the Sertoli cells and in the tubuli of mesonephros. No staining was detected in any other tissue of the fetal section (Fig. 3) . Negative controls showed no staining (Supplementary data, Fig. S3 ).
Expression of AMH forms in human fetal testis using immunofluorescence
In fetal testis, the different forms of pro-mature AMH (i.e. antibody AMH-39 and AMH-48) were expressed in the Sertoli cell cytoplasm of a 14-week-old fetus (Fig. 4) . In contrast, the mature C-terminal AMH (i.e. antibody AMH-29) was not detectable in the human fetal testis analysed (Fig. 4) . Furthermore, the commercially available AMH C-20 antibody (Santa Cruz Biotechnology) also showed expression in the Sertoli cell cytoplasm (Fig. 4) .
Application of AMH ELISA to human fetal serum
The 24/32 AMH ELISA detecting precursor AMH and pro-mature AMH forms was used. The mean (+SD) AMH levels of the four untreated fetal male serum samples were measured to 106.3 + 25.4 (ng/ml), whereas the same samples treated with SDS were measured to 4.7 + 0.5 ng/ml (Table II) . Since SDS will denature the pro-mature AMH form, but not the precursor AMH form, measurement following SDS treatment will reflect the fraction of precursor AMH in the fetal male serum, which accounts for 4.5% + 0.63 of the total AMH detected in this analysis (precursor AMH and pro-mature; Table II ). AMH levels in the fetal female serum samples were not detectable (data not shown).
Immunohistochemical staining of AMH forms in human immature GCs
Antibodies recognizing pro-mature AMH (i.e. AMH-39, AMH-48, AMH-72) were detected in the cytoplasm of GCs of human small antral follicles (Fig. 5) , whereas the mature C-terminal AMH (i.e. AMH-29) was located to the nucleus (Fig. 5) .
Expression of AMH forms in cultured human immature GCs using immunofluorescence
GCs from human small antral follicles cultured for 20 h expressed pro-mature AMH (AMH-39/48/72) in the cytoplasm, exemplified by AMH-48 (Fig. 6) . In contrast, the mature C-terminal AMH was also expressed in the nucleus in 10% of the cells (Fig. 7) , confirming the results obtained with IHC of follicles. Furthermore, the commercially available AMH C-20 antibody (Santa Cruz Biotechnology) also showed expression in the nucleus of cultured human GCs (not shown).
Western blot analysis of AMH forms in human fetal testis, mouse post-natal testis and human granulosa and cumulus cells
Western blot analyses of a human male fetal testis aged 8 weeks pc visualized by AMH-29 showed bands with Mw of 16 kDa and a weak detection of 12.5 and 55 kDa ( Fig. 8A; lane 1) . The AMH-29 antibody was blocked by surplus recombinant AMH, where after all the AMH-related bands disappeared and only the b-actin control band at 42 kDa was seen ( Fig. 8A; lane 2) . Analysis of the same male fetal testis visualized with AMH-48 detecting pro-mature AMH showed bands with Mw of 55, 16 and 12.5 (weak) kDa ( Fig. 8A; lane 3) . The AMH-48 antibody was blocked with surplus recombinant AMH, where after all the AMHrelated bands disappeared and only the 42 kDa b-actin control band was detected ( Fig. 8A; lane 4) .
Using human fetal testis visualized with AMH-29 again showed that mature C-terminal AMH was hardly detectable in the 12.5-kDa form but was detectable in a 16-kDa form, also a weak 55-kDa band was detected ( Fig. 8B; lane 1) . In contrast, in human GCs, mature C-terminal AMH was highly detectable in a 12.5-kDa form and also in a 16-kDa, and a weak 55-kDa, band was also detected (Fig. 8B; lane 2) . In human fetal testes, pro-mature AMH was highly detectable by AMH-48 antibody with bands of 98 and 55 kDa, though bands at 16 and 12.5 kDa (weak) were also detected (Fig. 8B, lane 3) . In GCs, pro-mature AMH was detectable by AMH-48 showing bands at 98, 55 (weak), 16 and 12.5 (weak) kDa (Fig. 8B, lane 4) . In both human fetal testes and GCs, promature AMH was highly detectable by antibody AMH-72 in a 55-kDa Expression of AMH subtypes form and weaker detection of the low Mw AMH forms at 16 and 12.5 kDa was also found (Fig. 8B, lanes 5 and 6) .
Using human fetal testis, the two antibodies against the mature C-terminal form, AMH-29 and AMH-1, stained a band of 16 kDa (Fig. 8C, lanes 1 and 4) . AMH-1 also stained one fainter band of 12.5 kDa (Fig. 8C, lane 4) . Testes tissue from 3-day-old mice did not stain strongly, but faint bands at 16 and 12.5 kDa were visualized with AMH-29 (Fig. 8C, lane 2) , and one faint band at 12.5 kDa was visualized with AMH-1 (Fig. 8C, lane 5) . Using the same testes samples (human and mouse, respectively) with antibodies AMH-48 and AMH-72 against the pro-mature form of AMH, many bands were visualized, probably also some resulting from non-specific binding. The most prominent bands were at 55, 35, 16 and 12.5 kDa (Fig. 8C, lanes 7, 8, 10 and 11) . As a control, human plasmin-cleaved AMH was used and when visualized with AHM-29 and AMH-1 strong bands at 12.5 kDa were seen (Fig. 8C, lanes 3 and 6) . Human Figure 3 Transverse section of a human male fetus aged 8 weeks pc. Antibody AMH-29 stained faintly in the testis (t) (A). Antibody AMH-48 stained strongly in the Sertoli cell cytoplasm of the testis (t) (B). Another section of the same fetus including the mesonephros, AMH-29 faintly stained the Sertoli cell cytoplasm (arrows) (C) and tubuli of mesonephros (arrowheads) (C1). AMH-48 stained the Sertoli cell cytoplasm (arrows) (D) and faintly stained tubules of mesonephros (arrowheads) (D1). Scale bars: (A) 1000 mm; (C) 50 mm; (C1) 25 mm. The scale of B, D and D1 corresponds to A, C and C1, respectively.
plasmin-cleaved AMH visualized with AMH-48 showed strong bands at 55, 35 and 12.5 kDa (Fig. 8C, lane 9) .
Human cumulus cells isolated from mature oocyte cumulus complexes collected at oocyte pick-up showed similar expression pattern as GCs-when visualized with AMH-29, bands of 16 and 12.5 kDa were seen (Fig. 8D, lane 1) . When visualized with AMH-48, the same two low Mw bands were seen more faintly; furthermore, the 35-kDa band was seen in the cumulus cells, which was not seen in GCs. 
Discussion
The development of specific antibodies binding to well-characterized epitopes on different parts of the AMH molecule has, for the first time, allowed a detailed study on the different molecular forms of AMH present in human reproductive organs of both genders. Surprisingly, this study has revealed a streaking difference in the expression of the biologically active AMH forms between human fetal testis and immature GCs visualized by IHC. Human fetal Sertoli cells almost exclusively express the pro-mature form of AMH with a low expression of the mature C-terminal form of AMH. In contrast to the human testes, human GCs from small antral follicles collected in adult ovaries express a mixture of both mature C-terminal and pro-mature AMH forms. These findings are supported by similar results of independent experiments using WB analysis of human fetal testes, mouse post-natal testis, human immature GCs and human cumulus cells. IFM analysis of cultured human GCs from immature follicles shows the same picture.
Despite that AMH is known to undergo post-translational proteolytic processing, the results of the WB analysis demonstrate a number of human AMH forms, which, to our knowledge, have not been reported previously. Human fetal testis and immature GCs showed under reducing conditions the known AMH forms with molecular weights of around 55 and 12.5 kDa. Furthermore, several other forms of AMH were found, the most prominent having molecular weights of 16, 35 and some with higher molecular weight than 70 kDa. It is especially noticeable that the 16-kDa AMH form appears to be prominent in both human fetal testis tissue and immature GCs. Plasmin-cleaved AMH clearly illustrated that the 16-kDa form is distinct from the 12.5-kDa form. Furthermore, the 16-kDa AMH form is detected both by the antibodies recognizing the pro-mature form and by the antibodies recognizing the mature C-terminal form, which indicates that an alternative cleavage of AMH takes place close to that of the 12.5-kDa mature C-terminal fragment. It is of interest to investigate the precise aa composition of this 16-kDa fragment and evaluate whether it possess biological activity. These molecular forms have all been shown to be specific to AMH by the effective blocking of staining by pre-incubating the antibodies with purified active and inactive AMH. Collectively, this demonstrates that AMH exists in a variety of forms that potentially may exert different physiological functions.
The difference in the presence of AMH forms between the two sexes may reflect the physiological function of AMH. In the fetal male, AMH is produced in the Sertoli cells with the function of inducing regression of the Müllerian ducts derivatives in mesonephros, where the AMHRII is expressed. The present data also demonstrate positive AMH staining in the mesonephros-derived tubules, directly showing that AMH acts in an endocrine manner. Expression of AMH in mesonephros was weaker when compared with the Sertoli cells, which may relate to the age of fetus and/or turnover of the bound AMH. It would be of interest to perform in situ hybridization to find out if AMH mRNA is located in the mesonephros. It appears that AMH in the male fetus is released in a precursor AMH inactive form and becomes active at its target. The result is supported by measuring the active forms of AMH in fetal serum of boys aged 16 -26 weeks pc, which show that the fraction of precursor AMH only counts for 4.5% of the total AMH measured by this assay, the remaining 95.5% is the pro-mature form. This may indicate that AMH becomes proteolytically cleaved in the circulation and is active upon arrival to the Müllerian duct derivatives. This notion is supported by observations by di Clemente et al. (2010) who showed that soluble AMHRII binds to pro-mature AMH and to active mature C-terminal AMH, but not to precursor AMH. These fetal human serum samples have been kept at 2808C for a number of years and have been thawed a few times for other measurements (Lutterodt et al., 2009 ). 
Expression of AMH subtypes
This prolonged storage and freeze/thaw could cause change in the molecular forms of AMH in the serum samples. However, the level of AMH measured with the new AMH assays as described in this study correlate well with the results obtained with former AMH assay from Diagnostic System Laboratories, USA (Lutterodt et al., 2009 ). Notwithstanding the above considerations, the multiple forms of AMH as demonstrated in the present study may become affected by freezing and thawing and thereby be part of an explanation for the recent difficulties in developing consistent AMH assays. Taken together, in the human male fetus, the effect of AMH may involve the release of precursor AMH, which requires a remarkable post-translational processing in circulation to become active upon arrival to the Müllerian duct derivatives, where AMHRII is expressed.
It has been shown that the pro-region of AMH cannot be detected after binding of cleaved mature C-terminal AMH to AMHRII expressed on controlled ovarian stimulation (COS) cells (di Clemente et al., 2010) . In this context, it is interesting to notice that we detected staining of both the AMH-29 and the AMH-39/48/72 in GCs. The AMH-39/48/72 antibodies were raised against epitopes on the pro-region of the molecule and should in theory not detect the active mature C-terminal. So unless some of the pro-mature AMH remains attached upon binding to the AMHRII on the surface of the Müllerian duct derivatives, antibody AMH-39/48/72 should not bind.
A range of human male fetuses, aged 8-19 weeks pc, were tested for the expression of the different forms of AMH and all revealed no or just a faint staining in the 1:50 dilution of the two antibodies detecting the mature C-terminal of AMH. Therefore, it cannot be excluded that a minor part of the AMH in the fetal testis is present in the mature form, but compared with the GC, there is a huge difference in the relative amount of the two AMH forms between the sexes. This fits with previous observations, where it has been reported that only 5-20% of the AMH expressed in human transfected COS cells is the mature C-terminal form (Pepinsky et al., 1988) . In addition, we found the mature C-terminal AMH was located to the nucleus in the IHC staining of GCs. In the cultured GCs, the location to the nucleus was only seen in a fraction of cells, which may indicate that luteinization of GCs had taken place during the culture period. The number of GCs in the cultures is limited by the relatively small amount and it is possible to aspirate form the follicles. Together, this suggests that this particular form of AMH as detected by the antibody AMH-29, which detects an epitope that becomes unmasked as the molecule becomes cleaved and active, may affect nuclear activity and cellular function. It can be speculated that the mature C-terminal of AMH may directly act as a transcription factor. AMH concentration in small antral follicles is up to a 1000 times higher than in the circulation, which suggests a local intrafollicular function of AMH (Andersen et al., 2010) . Furthermore, intrafollicular AMH levels in small antral follicles are decreasing with increasing follicle diameter and the levels is inversely correlated with inhibin-B levels, suggesting an interaction between these two hormones, which may be of importance for the follicular selection (Andersen et al., 2010) . The distribution of the active and non-active AMH subtypes in the follicular fluid is not known yet, though it would be of interest in the understanding of the intrafollicular regulation. Taken together, AMH acts in a paracrine and/or autocrine manner, but may also exert an intracrine function.
Collectively, these results demonstrate two new interesting observations in the puzzle on the physiology of AMH. (i) The mature C-terminal of AMH can hardly be detected in human fetal Sertoli cells, but is readily detected in GCs from human small antral follicles. (ii) The mature C-terminal of AMH is present in the nucleus in human GCs from small antral follicles, whereas the pro-mature form is expressed in the cytoplasm of GCs and Sertoli cells. These findings suggest that processing of AMH is a tightly regulated process, which is likely to be an important part of AMH function. 2) and pro-mature AMH with antibody AMH-48 (lanes 3 and 4) in human fetal testis. Mature C-terminal AMH stained strongly at 16 kDa and weakly at 12.5 and 55 kDa (lane 1). At least three forms of pro-mature AMH were detected at molecular masses of 55, 16 and 12.5 (weak) kDa (lane 3). The AMH-29/48 antibodies were blocked and only the control band was detected (lanes 2 and 4). (B) Detection of mature C-terminal AMH with AMH-29 (lanes 1 and 2), pro-mature AMH with AMH-48 (lanes 3 and 4) and AMH-72 (lanes 5 and 6) in human fetal testis (lanes 1, 3 and 5) and GCs (lanes 2, 4 and 6). In fetal testes, mature C-terminal AMH was hardly detectable in the 12.5-kDa form, but was detectable in a 16-kDa form, also a weak 55-kDa band was detected (lane 1). In GCs, in contrast, mature C-terminal AMH was highly detectable in the 12.5 form, 16 and 55 (weak) kDa bands were also seen (lane 2). Antibody AMH-48/72 showed a similar detection pattern in both testes and GCs: bands at 12.5 (weak), 16, 55 kDa were seen (lanes 3-6). AMH-48 also detected a 98-kDa band in both testes and GCs (lanes 3 and 4). (C) Detection of mature C-terminal AMH and pro-mature AMH in human fetal testis (lanes 1, 4, 7 and 10) and 3-day-old mouse testis (lanes 2, 5, 8 and 11) as a control plasmin-cleaved AMH was used (lanes 3, 6 and 9). In human testis, AMH-29 and AMH-1 stained a band at 16 kDa (lanes 1 and 4) . AMH-1 also stained one fainter band at 12.5 (lane 4). In mouse, AMH-29 stained bands at 12.5 (weak), and 16 kDa (lane 2), AMH-1 stained a band at 12.5 (weak) kDa (lane 5). In human and mice samples, respectively, detection of pro-mature AMH with antibody AMH-48 (lanes 7 and 8) and AMH-72 (lanes 10 and 11) showed many bands, the most prominent were at 12.5, 16, 35 and 55 kDa. As a control, human plasmin-cleaved AMH was used and showed strong 12.5 kDa bands when visualized with AMH-29 (lane 3) and AMH-1 (lane 6), bands at 55, 35 and 12.5 were seen when visualized with AMH-48 (lane 9). (D) Detection of mature C-terminal AMH and pro-mature AMH in human cumulus cells. AMH-29 and AMH-48 both detected bands at 12.5 and 16 kDa (lanes 1 and 2) . AMH-48 also stained a band at 35 kDa.
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